These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30933897)

  • 1. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
    Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
    J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression.
    Khoshkhabar R; Yazdani M; Hoda Alavizadeh S; Saberi Z; Arabi L; Reza Jaafari M
    Int Immunopharmacol; 2024 Aug; 137():112437. PubMed ID: 38870880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
    Wang W; Zhuang X; Liu W; Dong L; Sun H; Du G; Ye L
    Bioanalysis; 2018 Aug; 10(16):1335-1344. PubMed ID: 30130131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
    Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
    Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
    [No Abstract]   [Full Text] [Related]  

  • 6. Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.
    Ait-Belkacem R; Bol V; Hamm G; Schramme F; Van Den Eynde B; Poncelet L; Pamelard F; Stauber J; Gomes B
    SLAS Discov; 2017 Dec; 22(10):1182-1192. PubMed ID: 28557618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxgenase: a case of sulfur-substitution affecting distributions in blood cells.
    Wang W; Zhuang X; Sun H; Dong L; Liu Z; Du G; Ye L; Tian J
    Xenobiotica; 2019 Nov; 49(11):1338-1343. PubMed ID: 30507339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
    Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometric measurement of urinary kynurenine-to-tryptophan ratio in children with and without urinary tract infection.
    Yarbrough ML; Briden KE; Mitsios JV; Weindel AL; Terrill CM; Hunstad DA; Dietzen DJ
    Clin Biochem; 2018 Jun; 56():83-88. PubMed ID: 29679555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
    Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
    Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
    Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
    Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
    Matsuda A; Hata A; Tanaka A; Matsuda H
    Res Vet Sci; 2021 Jul; 137():159-162. PubMed ID: 33984619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
    Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
    Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival.
    Souissi S; Ghedira R; Macherki Y; Ben-Haj-Ayed A; Gabbouj S; Remadi Y; Sfar I; Chadli Z; Aouam K; Hassine M; Bouaouina N; Zakhama A; Hassen E
    Immun Inflamm Dis; 2022 Sep; 10(9):e690. PubMed ID: 36039641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
    Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
    Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.
    Wu D; Chen M; Chen S; Zhang S; Chen Y; Zhao Q; Xue K; Xue F; Chen X; Zhou M; Li H; Zheng J; Le Y; Cao H
    Clin Rheumatol; 2022 Oct; 41(10):3107-3117. PubMed ID: 35778590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.